ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
6,045.26
0.38%
US Tech 100
21,346.40
0.00%
Dow Jones
42,967.62
0.24%
Brent Oil
72.675
3.96%
Bitcoin
104,982.65
-0.89%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Ikena Oncology Inc (IKNA) Quote

Ikena Oncology Inc

Ikena Oncology Inc (IKNA)

NASDAQ
1.37
0.00
(0.00%)
Closed June 13 4:00PM
15 min delayed - Upgrade to Realtime
0.00
0.00
(0.00%)
After Hours: -
15 min delayed - Upgrade to Realtime

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
1.37
Bid
1.36
Ask
1.42
Volume
-
0.00 Day's Range 0.00
0.9707 52 Week Range 1.94
Market Cap
66.114M
Previous Close
1.37
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
97,514
Shares Outstanding
48,258,111
Dividend Yield
-
PE Ratio
-1.34
Earnings Per Share (EPS)
-1.02
Revenue
-
Net Profit
-49.23M

About Ikena Oncology Inc

Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD... Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.ikenaoncology.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Ikena Oncology Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IKNA. The last closing price for Ikena Oncology was $1.37. Over the last year, Ikena Oncology shares have traded in a share price range of $ 0.9707 to $ 1.94.

Ikena Oncology currently has 48,258,111 shares outstanding. The market capitalization of Ikena Oncology is $66.11 million. Ikena Oncology has a price to earnings ratio (PE ratio) of -1.34.

Ask ADVFN Intelligence (AI)

IKNA Latest News

More News

Form EFFECT - Notice of Effectiveness
Edgar (US Regulatory)
June 12 2025
IKNA (0.00%)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Edgar (US Regulatory)
June 11 2025
IKNA (0.00%)

Form S-4/A - Registration of securities, business combinations: [Amend]
Edgar (US Regulatory)
June 09 2025
IKNA (0.00%)

Form S-4/A - Registration of securities, business combinations: [Amend]
Edgar (US Regulatory)
May 30 2025
IKNA (0.00%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
May 08 2025
IKNA (0.00%)

Form S-4/A - Registration of securities, business combinations: [Amend]
Edgar (US Regulatory)
May 07 2025
IKNA (0.00%)

Form S-4/A - Registration of securities, business combinations: [Amend]
Edgar (US Regulatory)
April 21 2025
IKNA (0.00%)

Form S-4 - Registration of securities, business combinations
Edgar (US Regulatory)
March 18 2025
IKNA (0.00%)

Form ARS - Annual Report to Security Holders
Edgar (US Regulatory)
March 06 2025
IKNA (0.00%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
March 06 2025
IKNA (0.00%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.043.007518796991.331.51.33972921.4218986CS
40.2825.68807339451.091.51.061058411.25653124CS
120.043.007518796991.331.50.9707975141.19924611CS
26-0.31-18.45238095241.681.940.97071652581.45568006CS
52-0.39-22.15909090911.761.940.97071374151.54951652CS
156-2.62-65.6641604013.997.640.97071678882.487082CS
260-21.03-93.883928571422.437.610.97071654715.38664162CS

IKNA - Frequently Asked Questions (FAQ)

What is the current Ikena Oncology share price?
The current share price of Ikena Oncology is $ 1.37
How many Ikena Oncology shares are in issue?
Ikena Oncology has 48,258,111 shares in issue
What is the market cap of Ikena Oncology?
The market capitalisation of Ikena Oncology is USD 66.11M
What is the 1 year trading range for Ikena Oncology share price?
Ikena Oncology has traded in the range of $ 0.9707 to $ 1.94 during the past year
What is the PE ratio of Ikena Oncology?
The price to earnings ratio of Ikena Oncology is -1.34
What is the reporting currency for Ikena Oncology?
Ikena Oncology reports financial results in USD
What is the latest annual profit for Ikena Oncology?
The latest annual profit of Ikena Oncology is USD -49.23M
What is the registered address of Ikena Oncology?
The registered address for Ikena Oncology is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Ikena Oncology website address?
The website address for Ikena Oncology is www.ikenaoncology.com
Which industry sector does Ikena Oncology operate in?
Ikena Oncology operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACIUArmada Acquisition Corporation II
$ 10.10
(0.00%)
0
AACGATA Creativity Global
$ 0.8231
(0.00%)
0
AACBUArtius II Acquisition Inc
$ 10.36
(0.00%)
0
AACBArtius II Acquisition Inc
$ 10.13
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACIUArmada Acquisition Corporation II
$ 10.10
(0.00%)
0
AACGATA Creativity Global
$ 0.8231
(0.00%)
0
AACBUArtius II Acquisition Inc
$ 10.36
(0.00%)
0
AACBArtius II Acquisition Inc
$ 10.13
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACIUArmada Acquisition Corporation II
$ 10.10
(0.00%)
0
AACGATA Creativity Global
$ 0.8231
(0.00%)
0
AACBUArtius II Acquisition Inc
$ 10.36
(0.00%)
0
AACBArtius II Acquisition Inc
$ 10.13
(0.00%)
0

IKNA Discussion

View Posts
Monksdream Monksdream 1 month ago
IKNA under $2
👍️0
Monksdream Monksdream 2 months ago
IKNA under $2
👍️0
Monksdream Monksdream 4 months ago
IKNA under $2
👍️0
Monksdream Monksdream 6 months ago
IKNA under $2
👍️0
Monksdream Monksdream 8 months ago
IKNA under $2
👍️0
Monksdream Monksdream 11 months ago
IKNA under $2
👍️0
Monksdream Monksdream 11 months ago
IKNA under $2
👍️0
Monksdream Monksdream 11 months ago
IKNA under $2
👍️0
glenn1919 glenn1919 1 year ago
IKNA.....................................https://stockcharts.com/h-sc/ui?s=IKNA&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 1 year ago
IKNA under $2=
👍️0
Monksdream Monksdream 1 year ago
IKNA under $2
👍️0
herbied47 herbied47 2 years ago
$196.9M in cash, cash equivalents, and marketable securities, which it said would support operations well into 2026. $5.40 a share in cash
Market cap 37 million as of now. Price targets still between $8 and $11. Lots of upcoming catalyst Bullish
👍️0
herbied47 herbied47 2 years ago
Way over sold! https://finance.yahoo.com/news/broker-revenue-forecasts-ikena-oncology-100336585.html
👍️0
Tacostocks Tacostocks 2 years ago
It went down, because it didnt have the backing of Money hunt...
👍️0
Money hunt Money hunt 2 years ago
what happened here my short friend
👍️0
Tacostocks Tacostocks 2 years ago
Aged like milk eh
👍️0
AJ Freely AJ Freely 2 years ago
$IKNA - 👆Up 5.2% Pre-Market/ Current Price $5
To Acquire & Merge w/ Pionyr Immunotherapeutics
👍️0
Tartiaboy Tartiaboy 2 years ago
This is a very inactive board, but IKNA is worth keeping an eye on. I currently do not own any but am interested enough to follow it. Right now my biggest interest is in IKNA's new molecule IK-595- the RAF:MEK clamp. They intend to file and IND application in 2H2023. I see very big future potential for IK-595 and want to see how IKNA develops it's early clinical plan.

I am not too familiar with there lead drug so I am neutral regarding it.
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
IKNA look at this beast
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
IKNA monster
👍️0
crudeoil24 crudeoil24 4 years ago
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. It intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The Company is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. It also has early stage discovery programs in targeted oncology in the RAS pathway.
👍️0

Your Recent History

NASDAQ
IKNA
Ikena Oncology
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads